Crizotinib: From Chemical Entity to Anticancer Agent
Journal: Journal of Pharmacy and Pharmacology (Vol.5, No. 10)Publication Date: 2017-10-15
Authors : Xiaonan Jiang; Weihua Song; Qi Yang; Zhangqun Yang;
Page : 755-759
Keywords : ;
Abstract
Crizotinib is a mesenchymal-epithelial transition/anaplastic largecell kinase (MET/ALK) multi-targeted receptor tyrosine kinase inhibitor and has been rapidly and successfully developed as an inhibitor in ALK-rearranged NSCLC (non-small cell lung cancer). Lung cancer is the major cause of cancer-related mortality, accounting for over one quarter of cancer deaths. Lung cancers are generally divided into two main categories: SCLC (small cell lung cancer) and NSCLC. NSCLC accounts for approximately 85% of all lung cancers. ALK gene rearrangements are identified and targeted resulting in promising response rates for NSCLC in early studies. Considering the significance of Crizotinib in the treatment of NSCLC, the synthesis, pharmacodynamics, pharmacokinetics, therapeutic trials and adverse events are briefly overviewed in order to make more scholars, medical workers and patients have a more clear and comprehensive recognition on Crizotinib.
Other Latest Articles
- Diversity of Entomopathogenic Fungi in Argane Forest Soil and Their Potential to Manage Mediterranean Fruit Fly (Ceratitis capitata)
- Evaluation of the Effect of Citrus Lemon L. “Enter” on Blood Pressure in Hypertensive Patients
- Bioequivalence of Two Brands of Metformin 850 mg Coated Tablets in 12 Healthy Algerian Volunteers: A Pilot Study
- Profile of Patients Attended at the Genetic Service of a Special Care Institution in Brazil
- Attributional Styles in Adolescents with Transfusion-dependent Thalassemia
Last modified: 2022-07-04 09:49:12